UCB SA, the Belgian specialty pharmaceutical company, reported a 16% increase in revenue to about €3.9 billion in 2015. If exchange-rate effects were eliminated, the revenue increase would come to 9.0% ---Subscribe to MedNous to access this article--- Company News
